Cancer remains a leading cause of death among Americans with nearly two million newly diagnosed patients in 2018. As this trend continues, various cancer treatments are becoming more and more sought after in the fight against this complicated and deadly disease. To that end, the number of clinical trials is on the rise as are the challenges that stem from so much competition.

When biotech and pharma companies seek out facilities to run their clinical trials, the options may seem overwhelming and there is a lot to consider. In a recent article published by Fierce Biotech, Stephen Gately, PhD, Chief Executive Officer of TD2, has identified a few factors that make one facility stand out over another, such as the role of new technologies in the clinical trial process and how facilities are leveraging them.

Sites that are innovative in the way they analyze and use patient data are seeing great success, especially through new technologies in the clinical space such as Artificial Intelligence (AI). However, most sites aren’t at the stage to utilize these new technologies and human involvement is still necessary in one capacity or another in order to keep this data up to date. Those who are specialized and can maximize efficiency during the process have a leg up over the competition. In addition, clinical trial payment and big data analytics are trending technologies as well as patient engagement solutions, which include mobile health and electronic health records where adoption rates are around 60 percent.

There is a lot more to consider when it comes to competition in the clinical trial space – operational challenges, site selection, patient enrollment, and the research process timeline are just a few things to keep in mind when embarking on a new clinical trial. To learn more about TD2’s approach on planning a successful oncology clinical trial and how to design a study with the end goal in mind, read the full article here.